AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo

Blood Cancer Journal

Volumn 1, Issue 4, 2011, Pages

  Yu, M ^a   Gang, E J ^b   Parameswaran, R ^a   Stoddart, S ^a   Fei, F ^a   Schmidhuber, S ^a   Park, E ^b   Hsieh, Y T ^b   Yang, A S ^b   Groffen, J ^a,b   Heisterkamp, N ^a,b   Kim, Y M ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; NILOTINIB; PLERIXAFOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CHEMOTHERAPY; DRUG EFFICACY; HEMATOPOIESIS; IN VIVO STUDY; LETTER; MOUSE; NONHUMAN; STEM CELL;

EID: 84863779163     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.13     Document Type: Letter

References (8)

1. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318. (Pubitemid 40629073)
2. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 7: 1294-1300. (Pubitemid 36857336)
3. Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007; 6: 1249-1257. (Pubitemid 46831814)
4. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res 2006; 66: 5387-5393. (Pubitemid 43844965)
5. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
6. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
7. Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer 2007; 6: 67.
8. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-6224.